Women with type 2 diabetes. Diabetes mellitus due to underlying condition
Conditions
Interventions
Intervention 1: This study will be a three-arm randomized controlled trial. Participants will be randomly assigned to one of three groups. The first intervention group: High-Intensity Interval Cardio
n=13). HIICY group participants will train three days a week for 8 weeks. All training sessions will be conducted under the supervision of a qualified yoga instructor at the Faculty of Physical Educat
n=13), TIHY group participants will train three days a week for 8 weeks. All training sessions will be conducted under the supervision of a qualified yoga instructor at the Faculty of Physical Educati
Sponsors
University of Tabriz
Eligibility
Sex/Gender
Female
Age
35 Years to 65 Years
Inclusion criteria
Inclusion criteria: Having diabetic for>6 months Having a stable diet and currently taking oral antidiabetic medication Sedentary (25 kg/m2for the past 3 mo Diabetic will be defined as having a fasting glucose level of 126 mg/dL
Exclusion criteria
Exclusion criteria: Subjects will be excluded if they had a history of gastrointestinal, if they had renal, thyroid or liver disturbance; if they are pregnant or lactating pancreatic, or cardiovascular disease; If they are currently taking prebiotics, probiotics, antibiotics, antacids, alcohol, antidiarrheal, anti-inflammatory or laxative medicines If they will not attend training for more than three sessions; If they change their oral antidiabetic medication during the intervention
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in high-sensitivity C-reactive protein (hs-CRP). Timepoint: First intervention and 2 months after intervention. Method of measurement: At the beginning and end of the trial, 10 mL of venous blood samples will be collected between 9:00 AM and 7:00 AM following an overnight fast. The immunoturbidimetry assay will be utilized to characterize the serum hs-CRP level (Pars Azmoon Co., Tehran, Iran).;Tumor necrosis factor-alpha (TNF-a). Timepoint: First intervention and 2 months after intervention. Method of measurement: At the beginning and end of the trial, 10 mL of venous blood samples will be collected between 9:00 AM and 7:00 AM following an overnight fast. Based on the biotin double antibody sandwich technique, commercial enzyme-linked immunosorbent assay (ELISA) kits (Diaclone, Besancon, France) will be used to analyze the levels of TNF-a.;Changes in Interleukin 6 (IL-6). Timepoint: First intervention and 2 months after intervention. Method of measurement: At the beginning and end of the trial, 10 milliliters of venous blood samples will be collected between 7 AM and 9 AM after an overnight fast. Based on a double biotin sandwich antibody method, commercial ELISA kits (Diaclone, Besançon, France) will be used to analyze IL-6 levels.;Changes in Interleukin 10 (IL-10). Timepoint: First intervention and 2 months after intervention. Method of measurement: At the beginning and end of the trial, 10 milliliters of venous blood samples will be collected between 7 AM and 9 AM after an overnight fast. Based on a double biotin sandwich antibody method, commercial ELISA kits (Diaclone, Besançon, France) will be used to analyze IL-10 levels.;Changes in Low-Density Lipoprotein (LDL). Timepoint: First intervention and 2 months after intervention. Method of measurement: At the beginning and end of the trial, 10 ml of venous blood samples will be collected between 9 am and 7 am after an overnight fast. LDL concentration will be determined by enzymatic colorimetric methods (C | — |
Secondary
| Measure | Time frame |
|---|---|
| Waist circumference. Timepoint: First intervention and 2 months after intervention. Method of measurement: Waist circumference was measured using a non-elastic tape measure in the standing position at the midpoint of the lower edge of the lowest rib and the superior border of the iliac crest after normal breathing (without clothing). Waist circumference was measured according to standard methods described elsewhere.;Hip circumference. Timepoint: First intervention and 2 months after intervention. Method of measurement: The circumference of the hips will also be measured at the area of ??the greatest curvature of the buttocks without pressing the skin.;Body composition (FFM, FM, and FM%). Timepoint: First intervention and 2 months after intervention. Method of measurement: A body composition analyzer (Tanita BC-418, Tanita Corp., Tokyo, Japan) will be used to measure the participants' body composition.;Maximum oxygen consumption (VO2 max). Timepoint: First intervention and 2 months after intervention. Method of measurement: Aerobic fitness will also be assessed with a standardized submaximal treadmill walking protocol, which will be modified from the Balke 27 maximal protocol, to be appropriate for participants with various chronic conditions.;Body Mass Index (BMI). Timepoint: First intervention and 2 months after intervention. Method of measurement: BMI will also be calculated using the relevant formula by dividing weight (kg) by height squared (m2).;Body weight changes. Timepoint: First intervention and 2 months after intervention. Method of measurement: The patients' weight before and after the intervention will be measured using a Seca dial scale made in Germany with an accuracy of 100 grams with minimal clothing and no shoes. The patients' height will also be measured using a tape measure mounted on the wall with an accuracy of 0.1 cm. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMostafa Khani
University of Tabriz
Outcome results
None listed